Nexgenia’s reagent work published
in Analytical Chemistry

Posted on November 7 · Posted in News

Barrett J. Nehilla, a Senior Scientist at Nexgenia, is the lead author on a recent publication in Analytical Chemistry, an ACS journal. Find the publication here. The work describes Nexgenia’s binary reagent system for protein biomarker isolation.

Nexgenia awarded Phase 1 SBIR

Posted on May 7 · Posted in News

Nexgenia was awarded a Phase 1 SBIR grant from the National Institute of Allergy and Infectious Disease (NIAID) in February 2016. Nexgenia is collaborating with the Fred Hutchinson Cancer Research Center on this proposal. The project helps to commercialize our reagents for CAR T cell manufacturing.

Nexgenia Collaborates with Seattle Children’s
Research Institute

Posted on October 18 · Posted in News

Nexgenia and Seattle Children’s Research Institute Join Forces to Advance Immunotherapy Research Efforts Developing novel reagents designed to improve the efficiency and effectiveness of cancer immunotherapies Seattle, WA – October 19 – Nexgenia, a privately held biotechnology company focused on the development and manufacture of proprietary polymer-based reagents, is..
Read more

Nexgenia in December issue of
Seattle Business Magazine

Posted on December 12 · Posted in News

Cancer immunotherapy was highlighted in the Seattle Business Magazine’s December issue. Nexgenia was featured as a company with tools to help the manufacturing process of cell-based cancer immunotherapies. Read the full article here.

Nexgenia featured in Puget Sound
Business Journal

Posted on October 10 · Posted in News

Nexgenia was featured in the online news of the Puget Sound Business Journal. Read the article here.

Nexgenia Focuses on Cell Separations

Posted on · Posted in News

Nexgenia’s new CEO shifts focus to cell separations and immunotherapy product development. Read the press release from the UW C4C below. Nexgenia News Release